Pharmacological management of essential thrombocythemia

Bibliography

• Thiele J, Kvasnicka HM, Fuchs N, et al. Anagrelide-induced bone marrow changes during therapy of chronic myeloproliferative disorders with thrombocytosis. An immunohistochemical and morphometric study of sequential trephine biopsies. Haematologica 2003;88:1130-8
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM. A critical reappraisal of the WHO classification of the chronic myeloproliferative disorders. Leuk Lymphoma 2006;47:381-96
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM. Diagnostic differentiation of essential thrombocythaemia from thrombocythaemias associated with chronic idiopathic myelofibrosis by discriminate analysis of bone marrow features–a clinicopathological study on 272 patients. Histol Histopathol 2003;18:93-102
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM, Boeltken B, et al. Initial (prefibrotic) stages of idiopathic (primary) myelofibrosis (IMF) - a clinicopathological study. Leukemia 1999;13:1741-8
   PubMed Web of Science ®Google Scholar
• Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007;110:1092-7
   PubMed Web of Science ®Google Scholar
• Barbui T, Thiele J, Carobbio A, et al. Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis. Blood 2012;120:569-71
   PubMed Web of Science ®Google Scholar
• Ejerblad E, Kvasnicka HM, Thiele J, et al. Diagnosis according to World Health Organization determines the long-term prognosis in patients with myeloproliferative neoplasms treated with anagrelide: results of a prospective long-term follow-up. Hematology (Am Soc Hematol Educ Program) 2013;18(1):8-13
   Google Scholar
• Passamonti F, Thiele J, Girodon F, et al. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the international working group on myelofibrosis research and treatment. Blood 2012;120(6):1197-201
   PubMed Web of Science ®Google Scholar
• Wilkins BS, Erber WN, Bareford D, et al. Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood 2008;111:60-70
   PubMed Web of Science ®Google Scholar
• Campbell PJ, Bareford D, Erber WN, et al. Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. J Clin Oncol 2009;27:2991-9
   PubMed Web of Science ®Google Scholar
• Carobbio A, Finazzi G, Thiele J, et al. Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia. Am J Hematol 2012;87:203-4
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM, Mullauer L, et al. Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. Blood 2011;117:5710-18
   PubMed Web of Science ®Google Scholar
• Carobbio A, Antonioli E, Guglielmelli P, et al. Leukocytosis and risk stratification assessment in essential thrombocythemia. J Clinical Oncol 2008;26:2732-6
   PubMed Web of Science ®Google Scholar
• Barbui T, Thiele J, Vannucchi AM, Tefferi A. Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia. Leukemia 2013; Epub ahead of print
   Google Scholar
• Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer 2007;109:68-76
   PubMed Web of Science ®Google Scholar
• Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005;353:33-45
   PubMed Web of Science ®Google Scholar
• Jensen MK, de Nully Brown P, Nielsen OJ, et al. Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area. Eur J Haematol 2000;65:132-9
   PubMed Web of Science ®Google Scholar
• Carobbio A, Finazzi G, Antonioli E, et al. Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria. Blood 2010;116:1051-5
   PubMed Web of Science ®Google Scholar
• Gisslinger H, Gotic M, Holowiecki J, et al. Anagrelide compared to hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood 2013;121:1720-8
   PubMed Web of Science ®Google Scholar
• Barbui T, Finazzi G, Carobbio A, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood 2012;120:5128-33
   PubMed Web of Science ®Google Scholar
• Tefferi A, Gangat N, Wolanskyj AP, et al. 20 + yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosis. Eur J Haematol 2008;80:386-90
   PubMedGoogle Scholar
• Passamonti F, Rumi E, Arcaini L, et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica 2008;93:1645-51
   PubMed Web of Science ®Google Scholar
• Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clinical Oncology 2011;29:3179-84
   PubMed Web of Science ®Google Scholar
• Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clinical Oncology 2011;29:761-70
   PubMed Web of Science ®Google Scholar
• Buxhofer-Ausch V, Gisslinger H, Thiele J, et al. Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: an international study of 264 patients. Am J Hematol 2012;87:669-72
   PubMed Web of Science ®Google Scholar
• De Stefano V, Za T, Rossi E, et al. Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation. Ann Hematol 2010;89:141-6
   PubMed Web of Science ®Google Scholar
• Dahabreh IJ, Zoi K, Giannouli S, et al. Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia. Leuk Res 2009;33:67-73
   PubMed Web of Science ®Google Scholar
• Carobbio A, Thiele J, Passamonti F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood 2011;117:5857-9
   PubMed Web of Science ®Google Scholar
• Budde U, van Genderen PJ. Acquired von Willebrand disease in patients with high platelet counts. Semin Thromb Hemost 1997;23:425-31
   PubMed Web of Science ®Google Scholar
• Landolfi R, Marchioli R. European collaboration on low-dose aspirin in polycythemia vera (ECLAP): a randomized trial. Semin Thromb Hemost 1997;23:473-8
   PubMed Web of Science ®Google Scholar
• Alvarez-Larran A, Cervantes F, Pereira A, et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood 2010;116:1205-10. quiz 387
   PubMed Web of Science ®Google Scholar
• Landolfi R, Di Gennaro L, Novarese L, et al. Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: current insights and rationale for future studies. Semin Thromb Hemost 2006;32:251-9
   PubMedGoogle Scholar
• Patrono C. Aspirin continues to attract research and debate, 115 years after its synthesis. Rev Esp Cardiol 2013;66(4):251-4
   PubMedGoogle Scholar
• van Genderen PJ, van Vliet HH, Prins FJ, et al. Excessive prolongation of the bleeding time by aspirin in essential thrombocythemia is related to a decrease of large von Willebrand factor multimers in plasma. Ann Hematol 1997;75:215-20
   PubMed Web of Science ®Google Scholar
• Finazzi G, Carobbio A, Thiele J, et al. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the. 2008 WHO criteria. Leukemia 2012;26:716-19
   PubMed Web of Science ®Google Scholar
• Vaiopoulos G, Terpos E, Viniou N, et al. Behcet's disease in a patient with chronic myelogenous leukemia under hydroxyurea treatment: a case report and review of the literature. Amn J Hematology 2001;66:57-8
   PubMed Web of Science ®Google Scholar
• Su L, Zheng J, Xiu L, et al. Antineutrophil cytoplasmic antibody-associated vasculitis in a patient with polycythemia vera after long-term hydroxyurea treatment. Leuk Lymphoma 2011;52:2193-4
   PubMed Web of Science ®Google Scholar
• Ravandi-Kashani F, Cortes J, Cohen P, et al. Cutaneous ulcers associated with hydroxyurea therapy in myeloproliferative disorders. Leuk Lymphoma 1999;35:109-18
   PubMed Web of Science ®Google Scholar
• Mendonca R, Gueiros LA, Capellaro K, et al. Oral lesions associated with hydroxyurea treatment. Indian J Dent Res 2011;22:869-70
   PubMedGoogle Scholar
• Nofal A, El-Din ES. Hydroxyurea-induced dermatomyositis: true amyopathic dermatomyositis or dermatomyositis-like eruption? Int J Dermatol 2012;51:535-41
   PubMed Web of Science ®Google Scholar
• Richard M, Truchetet F, Friedel J, et al. Skin lesions simulating chronic dermatomyositis during long-term hydroxyurea therapy. J Amn Acad Dermatol 1989;21:797-9
   PubMed Web of Science ®Google Scholar
• Antonioli E, Guglielmelli P, Pieri L, et al. Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN. Amn J Hematology 2012;87:552-4
   PubMed Web of Science ®Google Scholar
• Randi ML, Ruzzon E, Luzzatto G, et al. Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders. Haematologica 2005;90:261-2
   PubMed Web of Science ®Google Scholar
• Barosi G, Birgegard G, Finazzi G, et al. A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. Br J Haematol 2010;148:961-3
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM, Ollig S, et al. Anagrelide does not exert a myelodysplastic effect on megakaryopoiesis: a comparative immunohistochemical and morphometric study with hydroxyurea. Histol Histopathol 2005;20:1071-6
   PubMed Web of Science ®Google Scholar
• Weinfeld A, Swolin B, Westin J. Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications. Eur J Haematol 1994;52:134-9
   PubMed Web of Science ®Google Scholar
• Passamonti F, Malabarba L, Orlandi E, et al. Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. Haematologica 2003;88:13-18
   PubMed Web of Science ®Google Scholar
• West WO. Hydroxyurea in the treatment of polycythemia vera: a prospective study of 100 patients over a 20-year period. South Med J 1987;80:323-7
   PubMed Web of Science ®Google Scholar
• Chim CS, Kwong YL, Lie AK, et al. Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia. Arch Intern Med 2005;165:2651-8
   PubMed Web of Science ®Google Scholar
• Najean Y, Rain JD, Lejeune F, et al. Treatment of polycythemia. II.– Comparison of hydroxyurea with pipobroman in 294 patients less than 65 years of age. Ann Med Internet 1998;149:94-100
   PubMedGoogle Scholar
• Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood 2005;105:2664-70
   PubMed Web of Science ®Google Scholar
• Kiladjian JJ, Chevret S, Dosquet C, et al. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in. 1980;J Clinical Oncol 2011;29:3907-13
   Web of Science ®Google Scholar
• Bjorkholm M, Derolf AR, Hultcrantz M, et al. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J Clinical Oncol 2011;29:2410-15
   PubMed Web of Science ®Google Scholar
• Besses C, Kiladjian JJ, Griesshammer M, et al. Cytoreductive treatment patterns for essential thrombocythemia in Europe. Analysis of 3643 patients in the EXELS study. Leuk Res 2013;37:162-8
   PubMed Web of Science ®Google Scholar
• Cortelazzo SFG, Ruggeri M, Vestri O, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995;332:1132-6
   PubMed Web of Science ®Google Scholar
• Kiladjian JJ, Besses C, Griesshammer M, et al. Efficacy and safety of cytoreductive therapies in patients with essential thrombocythaemia aged > 80 years. an interim analysis of the EXELS study. Clin Drug Investig 2013;33:55-63
   PubMed Web of Science ®Google Scholar
• Barbui T, Finazzi MC, Finazzi G. Front-line therapy in polycythemia vera and essential thrombocythemia. Blood Rev 2012;26:205-11
   PubMed Web of Science ®Google Scholar
• Zalcberg IR, Ayres-Silva J, de Azevedo AM, et al. Hydroxyurea dose impacts hematologic parameters in polycythemia vera and essential thrombocythemia but does not appreciably affect JAK2-V617F allele burden. Haematologica 2011;96:e18-20
   Web of Science ®Google Scholar
• Kiladjian JJ, Chomienne C, Fenaux P. Interferon-alpha therapy in bcr-ablnegative myeloproliferative neoplasms. Leukemia 2008;22:1990-8
   PubMed Web of Science ®Google Scholar
• Silver RT, Kiladjian JJ, Hasselbalch HC. Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis. Expert Rev Hematol 2013;6:49-58
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian H, Manshouri T, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 2009;27:5418-24
   PubMed Web of Science ®Google Scholar
• Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008;112:3065-72
   PubMed Web of Science ®Google Scholar
• Lengfelder E, Griesshammer M, Hehlmann R. Interferon-alpha in the treatment of essential thrombocythemia. Leuk Lymphoma 1996;22(Suppl 1):135-42
   PubMed Web of Science ®Google Scholar
• Samuelsson J, Mutschler M, Birgegard G, et al. Limited effects on JAK2 mutational status after pegylated interferon alpha-2b therapy in polycythemia vera and essential thrombocythemia. Haematologica 2006;91:1281-2
   PubMed Web of Science ®Google Scholar
• Samuelsson J, Hasselbalch H, Bruserud O, et al. A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life. Cancer 2006;106:2397-405
   PubMed Web of Science ®Google Scholar
• Harrison CN, Robinson SE. Myeloproliferative disorders in pregnancy. Hematol Oncol Clinic North Am 2011;25:261-75. vii
   PubMed Web of Science ®Google Scholar
• Hong Y, Wang G, Del Arroyo AG, et al. Comparison between anagrelide and hydroxycarbamide in their activities against haematopoietic progenitor cell growth and differentiation: selectivity of anagrelide for the megakaryocytic lineage. Leukemia 2006;20:1117-22
   PubMed Web of Science ®Google Scholar
• Palmblad J, Bjorkholm M, Kutti J, et al. TPO, but not soluble-IL-6 receptor, levels increase after anagrelide treatment of thrombocythemia in chronic myeloproliferative disorders. Int J Med Sci 2008;5:87-91
   PubMedGoogle Scholar
• Cacciola RR, Francesco ED, Giustolisi R, et al. Effects of anagrelide on platelet factor 4 and vascular endothelial growth factor levels in patients with essential thrombocythemia. Br J Haematol 2004;126:885-6
   PubMedGoogle Scholar
• Fruchtman SM, Petitt RM, Gilbert HS, et al. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders. Leuk Res 2005;29:481-91
   PubMed Web of Science ®Google Scholar
• Birgegard G, Bjorkholm M, Kutti J, et al. Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders. Haematologica 2004;89:520-7
   PubMed Web of Science ®Google Scholar
• Steurer M, Gastl G, Jedrzejczak WW, et al. Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile. Cancer 2004;101:2239-46
   PubMed Web of Science ®Google Scholar
• Penninga E, Jensen BA, Hansen PB, et al. Anagrelide treatment in 52 patients with chronic myeloproliferative diseases. Clin Lab Haematol 2004;26:335-40
   PubMedGoogle Scholar
• Laguna MS, Kornblihtt LI, Marta RF, et al. Effectiveness of anagrelide in the treatment of symptomatic patients with essential thrombocythemia. Clin Appl Thromb Hemost 2000;6:157-61
   PubMed Web of Science ®Google Scholar
• Mills AK, Taylor KM, Wright SJ, et al. Efficacy, safety and tolerability of anagrelide in the treatment of essential thrombocythaemia. Aust NZ J Med 1999;29:29-35
   PubMedGoogle Scholar
• Petrides PE, Beykirch MK, Trapp OM. Anagrelide, a novel platelet lowering option in essential thrombocythaemia: treatment experience in 48 patients in Germany. Eur J Haematol 1998;61:71-6
   PubMed Web of Science ®Google Scholar
• Anagrelide Study Group. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am J Med 1992;92:69-76
   PubMed Web of Science ®Google Scholar
• Petitt RM, Silverstein MN, Petrone ME. Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders. Semin Hematol 1997;34:51-4
   PubMed Web of Science ®Google Scholar
• Petrides PE. Anagrelide: a decade of clinical experience with its use for the treatment of primary thrombocythaemia. Expert Opin Pharmacother 2004;5:1781-98
   PubMed Web of Science ®Google Scholar
• Hultdin M, Sundstrom G, Wahlin A, et al. Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment. Med Oncol 2007;24:63-70
   PubMed Web of Science ®Google Scholar
• Gugliotta L, Tieghi A, Tortorella G, et al. Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia. Leuk Res 2011;35:1557-63
   PubMed Web of Science ®Google Scholar
• Besses C, Zeller W, Alvarez et al. Pharmacokinetics and tolerability of anagrelide hydrochloride in young (18 - 50 years) and elderly (>/= 65 years) patients with essential thrombocythemia. Int J Clinical Pharmacol Ther 2012;50:787-96
   PubMed Web of Science ®Google Scholar
• Gisslinger H. Essential thrombocythemia: a prospective analysis of efficacy and safety of anagrelide for long term treatment in patients below and above the age of 60 years. ASH Annu Meet Abstr 2007. 110:3561
   Google Scholar
• Hultcrantz M, Kristinsson SY, Andersson TM, et al. Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from. 1973 to 2008: a population-based study. J Clinical Oncol 2012;30:2995-3001
   PubMed Web of Science ®Google Scholar
• Berk PD, Goldberg JD, Silverstein MN, et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med 1981;304:441-7
   PubMed Web of Science ®Google Scholar
• Modan B, Lilienfeld AM. Polycythemia vera and leukemia–the role of radiation treatment. A study of 1222 patients. Medicine 1965;44:305-44
   PubMed Web of Science ®Google Scholar
• Radaelli F, Onida F, Rossi FG, et al. Second malignancies in essential thrombocythemia (ET): a retrospective analysis of 331 patients with long-term follow-up from a single institution. Hematol 2008;13:195-202
   PubMed Web of Science ®Google Scholar
• D'Adda M, Micheletti M, Drera M, et al. The combined use of hydroxyurea and anagrelide allows satisfactory hematologic control in patients with chronic myeloproliferative disorders and thrombocytosis: a report on 13 patients with poor tolerance to hydroxyurea monotherapy. Leuk Lymphoma 2008;49:2216-18
   PubMed Web of Science ®Google Scholar
• Christoforidou A, Pantelidou D, Anastasiadis A, et al. Hydroxyurea and anagrelide combination therapy in patients with chronic myeloproliferative diseases resistant or intolerant to monotherapy. Acta Haematol 2008;120:195-8
   PubMed Web of Science ®Google Scholar
• Baerlocher GM, Leibundgut EO, Ayran C, et al. Imetelstat rapidly induces and maintains substantial hematologic and molecular responses in patients with essential thrombocythemia (ET) who are refractory or intolerant to prior therapy: preliminary phase II results. ASH Annu Meet Abstr 2012. 120:179
   Google Scholar
• Barosi G, Birgegard G, Finazzi G, et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood 2009;113:4829-33
   PubMed Web of Science ®Google Scholar
• Hernandez-Boluda JC, Alvarez-Larran A, Gomez M, et al. Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia. Br J Haematol 2011;152:81-8
   PubMed Web of Science ®Google Scholar
• Fallowfield L, Jenkins V. Communicating sad, bad, and difficult news in medicine. Lancet 2004;363:312-19
   PubMed Web of Science ®Google Scholar